Coya Therapeutics, Inc. (COYA)
NASDAQ: COYA · Real-Time Price · USD
4.050
+0.040 (1.00%)
At close: Apr 6, 2026, 4:00 PM EDT
4.140
+0.090 (2.22%)
After-hours: Apr 6, 2026, 4:23 PM EDT
Coya Therapeutics Revenue
In the year 2025, Coya Therapeutics had annual revenue of $7.95M with 123.57% growth. Coya Therapeutics had revenue of $3.96M in the quarter ending December 31, 2025, with 202,768.80% growth.
Revenue (ttm)
$7.95M
Revenue Growth
+123.57%
P/S Ratio
11.96
Revenue / Employee
$993,219
Employees
8
Market Cap
95.00M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 7.95M | 4.39M | 123.57% |
| Dec 31, 2024 | 3.55M | -2.45M | -40.79% |
| Dec 31, 2023 | 6.00M | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Q32 Bio | 53.74M |
| Verrica Pharmaceuticals | 35.58M |
| Seer, Inc. | 16.58M |
| Pyxis Oncology | 13.86M |
| Seres Therapeutics | 789.00K |
| Spruce Biosciences | 697.00K |
COYA News
- 4 days ago - Coya Therapeutics Announces Planned Board Transition and Appointment of Mark H. Pavao as Independent Director - Business Wire
- 19 days ago - Coya Therapeutics Announces Publication Demonstrating Regulatory T-Cell Dysfunction and Systemic Inflammation in Frontotemporal Dementia, Supporting Mechanistic Rationale for COYA 302 Immune-Restoring Therapy - Business Wire
- 21 days ago - Coya Therapeutics Provides a Corporate Update and Reports Fiscal 2025 Financial Results - Business Wire
- 7 weeks ago - Coya Therapeutics to Host Webinar with Leading Medical Experts on Amyotrophic Lateral Sclerosis (ALS) Drug Development, Patient Landscape, and Ongoing Clinical Trial - Business Wire
- 2 months ago - Coya Therapeutics Announces $11.1 Million Private Placement - Business Wire
- 2 months ago - Coya Therapeutics CEO Dr. Arun Swaminathan Issues Letter to Stockholders - Business Wire
- 3 months ago - Coya Therapeutics Announces Results of Investigator-Initiated Study of LD IL-2 and CTLA4-Ig Demonstrating Treg Enhancement and Cognitive Stability in Frontotemporal Dementia Patients - Business Wire
- 3 months ago - Coya Therapeutics Announces U.S. FDA Acceptance of Investigational New Drug (IND) Application for COYA 302 for the Treatment of Frontotemporal Dementia (FTD) - Business Wire